These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31451507)

  • 1. Potent LpxC Inhibitors with
    Krause KM; Haglund CM; Hebner C; Serio AW; Lee G; Nieto V; Cohen F; Kane TR; Machajewski TD; Hildebrandt D; Pillar C; Thwaites M; Hall D; Miesel L; Hackel M; Burek A; Andrews LD; Armstrong E; Swem L; Jubb A; Cirz RT
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
    Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
    mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
    Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
    Piizzi G; Parker DT; Peng Y; Dobler M; Patnaik A; Wattanasin S; Liu E; Lenoir F; Nunez J; Kerrigan J; McKenney D; Osborne C; Yu D; Lanieri L; Bojkovic J; Dzink-Fox J; Lilly MD; Sprague ER; Lu Y; Wang H; Ranjitkar S; Xie L; Wang B; Glick M; Hamann LG; Tommasi R; Yang X; Dean CR
    J Med Chem; 2017 Jun; 60(12):5002-5014. PubMed ID: 28549219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
    Erwin AL
    Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based discovery of LpxC inhibitors.
    Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.
    Cohen F; Aggen JB; Andrews LD; Assar Z; Boggs J; Choi T; Dozzo P; Easterday AN; Haglund CM; Hildebrandt DJ; Holt MC; Joly K; Jubb A; Kamal Z; Kane TR; Konradi AW; Krause KM; Linsell MS; Machajewski TD; Miroshnikova O; Moser HE; Nieto V; Phan T; Plato C; Serio AW; Seroogy J; Shakhmin A; Stein AJ; Sun AD; Sviridov S; Wang Z; Wlasichuk K; Yang W; Zhou X; Zhu H; Cirz RT
    ChemMedChem; 2019 Aug; 14(16):1560-1572. PubMed ID: 31283109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
    Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
    J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
    Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
    Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P; Hong J
    Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
    Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
    Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
    Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
    Pirrung MC; Tumey LN; McClerren AL; Raetz CR
    J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations Reducing
    Jones AK; Caughlan RE; Woods AL; Uehara K; Xie L; Barnes SW; Walker JR; Thompson KV; Ranjitkar S; Lee PS; Dean CR
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
    Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
    Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
    Zhang J; Zhang L; Li X; Xu W
    Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC.
    Kline T; Andersen NH; Harwood EA; Bowman J; Malanda A; Endsley S; Erwin AL; Doyle M; Fong S; Harris AL; Mendelsohn B; Mdluli K; Raetz CR; Stover CK; Witte PR; Yabannavar A; Zhu S
    J Med Chem; 2002 Jul; 45(14):3112-29. PubMed ID: 12086497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
    Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.